Vazyme(688105)2025-01-16 09:04Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between -20 million and -12 million RMB, a reduction in loss of 50.96 million to 58.96 million RMB compared to the same period last year, representing a year-on-year reduction in loss of 71.81% to 83.09%[2]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to be between -85 million and -77 million RMB, a reduction in loss of 107.73 million to 115.73 million RMB compared to the same period last year, representing a year-on-year reduction in loss of 55.90% to 60.05%[2]. - The total profit for the year 2023 was -115.71 million RMB, with a net profit attributable to shareholders of the parent company of -70.96 million RMB[3]. Operational Improvements - The company has implemented measures such as information system construction and business process optimization, leading to improved operational efficiency compared to the previous period[5]. - The company has seen a significant decrease in asset impairment losses compared to the previous period[5]. R&D Investment - R&D expenditure has decreased year-on-year, but the company maintains a relatively high R&D investment intensity, focusing on areas such as neurological detection and microfluidic product lines[5]. Revenue and Subsidies - Revenue related to government subsidies has significantly decreased during the reporting period[5]. Earnings Forecast and Risks - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast[6]. - The earnings forecast is based on preliminary internal calculations and has not been audited by a registered accountant[6]. - Investors are advised to pay attention to investment risks as the final audited annual report will provide more accurate information[6].